DefenCath® (taurolidine and heparin) catheter lock solution is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.

Beth Zelnick Kaufman, Esq.

January 10, 2024

Beth Zelnick Kaufman was appointed as EVP, Chief Legal Officer, and Corporate Secretary in December 2023. She leads the company’s legal and compliance activities. Prior to joining CorMedix, she most recently served as Chief Legal and Administrative Officer and Corporate Secretary of Akorn Pharmaceuticals, a specialty and generic pharmaceuticals company. Ms. Zelnick Kaufman also served as Chief Legal Officer of The Broad Institute of MIT & Harvard and in several roles at Amneal Pharmaceuticals, a publicly traded global generics, biosimilars, and branded pharmaceuticals company, including roles as Assistant General Counsel, Vice President, Legal Affairs, and Head of Government Affairs. Ms. Zelnick Kaufman holds a Juris Doctor degree from New York University Law School and a Bachelor of Arts degree from Amherst College.